Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.46 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 9/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665651 | 0.82 | ALOX15 (0.47) | ALOX15ALDH1A1HPGDKMT2ATOP2A | |
| SCHEMBL891609 | 0.82 | ALDH1A1 (0.60) | ALDH1A1HPGDTOP2AAOX1 | |
| SCHEMBL1665126 | 0.80 | ALDH1A1 (0.48) | ALOX15ALDH1A1HPGDKMT2ATOP2A | |
| SCHEMBL14782232 | 0.80 | ALDH1A1 (0.46) | ALDH1A1ALDH1A3ALDH3A1HPGDAOX1 | |
| SCHEMBL9225446 | 0.75 | TOP2A (0.64) | ALOX15ALDH1A1KMT2ATOP2A | |
| SCHEMBL177168 | 0.75 | FDPS (0.54) | ALDH1A1ALDH1A3ALDH3A1HPGDKMT2A | |
| SCHEMBL493460 | 0.74 | ALDH1A1 (0.60) | ALDH1A1ALDH1A3ALDH3A1HPGDAOX1 | |
| SCHEMBL1665645 | 0.74 | KMT2A (0.74) | ALDH1A1ALDH1A3HPGDKMT2A | |
| SCHEMBL7443903 | 0.74 | KMT2A (0.51) | ALOX15ALDH1A1HPGDKMT2A | |
| SCHEMBL891219 | 0.74 | TOP2A (0.66) | ALDH1A1TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493905-B1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | WARNER CHILCOTT CO LLC (PR) | 2016-11-30 | — | — | EP | disclosed |
| US-8822435-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140194389-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-8710215-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130035482-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2013-02-07 | — | — | US | disclosed |
| US-8314081-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2493905-A1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | Warner Chilcott Company, LLC (PR) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011056589-A1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | WARNER CHILCOTT COMPANY, LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110098251-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194389-A1 | BISPHOSPHONATE COMPOUNDS | BPGM, PPIP5K2, PTEN | ALOX15 1639/4885ALDH1A1 2404/4885ALDH1A3 3800/4885 |
| US-20110098251-A1 | BISPHOSPHONATE COMPOUNDS | BPGM, PPIP5K2, PTEN | ALOX15 1639/4885ALDH1A1 2404/4885ALDH1A3 3800/4885 |
| US-20130035482-A1 | BISPHOSPHONATE COMPOUNDS | BPGM, PPIP5K2, PTEN | ALOX15 1639/4885ALDH1A1 2404/4885ALDH1A3 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.